论文部分内容阅读
核苷酸切除修复交叉互补组1(ERCC1)是核苷酸切除修复途径的限速酶,ERCC表达与多种恶性肿瘤的化疗疗效及预后相关联,ERCC1单核苷酸多态性与肿瘤患者对化疗药物的敏感程度和预后有关,有助于预测化疗反应性。
Nucleotide excision repair cross-complementing group 1 (ERCC1) is a rate-limiting enzyme in the nucleotide excision repair pathway. ERCC expression is associated with the chemotherapeutic efficacy and prognosis of various malignancies. The relationship between ERCC1 SNP and tumor patients Sensitivity to chemotherapeutic drugs is associated with prognosis, which is helpful to predict response to chemotherapy.